A new generation of Alzheimer’s drugs “likely have no clinically meaningful benefit", according to a gold-standard review. It suggests billions of pounds globally may have been wasted in researching the so-called amyloid hypothesis - which assumed that reducing the build-up of the key protein in the brain could halt the progression of dementia. There had been huge hope among dementia patients and experts after pharmaceutical firms posted data from clinical trials claiming that two